PHASE II STUDY OF CLADRIBINE AND LOW-DOSE ARAC ALTERNATING WITH DECITABINE IN OLDER PATIENTS WITH AML.

EHA Library, Tapan Kadia, 133175

RESULTS OF A PHASE 1B STUDY OF VENETOCLAX PLUS DECITABINE OR AZACITIDINE IN UNTREATED ACUTE MYELOID LEUKEMIA PATIENTS ≥65 YEARS INELIGIBLE FOR STANDARD INDUCTION THERAPY

EHA Library, Daniel A Pollyea, 133180

IDENTIFICATION OF NOVEL B CELL RECEPTOR ANTIGENS IN CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Elisa ten Hacken, 133183

CXCL12 ANTAGONISM BY THE L-RNA APTAMER OLAPTESED PEGOL IS EFFECTIVE AS A MOBILIZING AND THERAPEUTIC AGENT IN A MURINE CHRONIC LYMPHOCYTIC LEUKEMIA MODEL

EHA Library, Tanja Hartmann, 133184

THE PAN-PIM KINASE INHIBITOR LGB321 TARGETS APOPTOTIC PATHWAYS AND MICROENVIRONMENTAL INTERACTIONS IN CLL

EHA Library, Sarah Decker, 133185

IN VIVO CHARACTERIZATION OF LYN KINASE IN THE PATHOGENESIS OF CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Hien NGUYEN, 133186

MICROENVIRONMENTAL STROMAL CELLS TRIGGER HYPOXIA SIGNALLING IN CLL CELLS – A MECHANISM THAT PROVIDES PROTECTION FROM APOPTOSIS AND CAN BE TARGETED THERAPEUTICALLY

EHA Library, Daniel Mertens, 133187

THE T-CELL/CLL/MACROPHAGE TRIAD SHAPES A SUPPORTIVE TUMOR MICROENVIRONMENT IN CLL

EHA Library, Martijn van Attekum, 133190

METABOLIC ALTERATIONS INDUCED BY IBRUTINIB IN CLL CELLS AS A BIOCHEMICAL BASIS FOR MECHANISM-BASED DRUG COMBINATION TO ENHANCE THERAPEUTIC ACTIVITY

EHA Library, Helene Pelicano, 133191

CD49D EXPRESSION IMPACTS ON THE IBRUTINIB-INDUCED LYMPHOCYTOSIS IN CHRONIC LYMPHOCYTIC LEUKEMIA: A ROLE OF BCR-MEDIATED INSIDE-OUT VLA-4 INTEGRIN ACTIVATION

EHA Library, Valter Gattei, 133194

LONG-TERM FOLLOW-UP OF THE NEXT GENERATION PI3K-DELTA INHIBITOR TGR-1202 DEMONSTRATES SAFETY AND HIGH RESPONSE RATES IN CLL: INTEGRATED-ANALYSIS OF TGR-1202 MONOTHERAPY AND COMBINED WITH UBLITUXIMAB

EHA Library, Anthony Mato, 133195

PRESENCE OF MULTIPLE UNMUTATED IGHV REARRANGEMENTS IN CLL PATIENTS IS ASSOCIATED WITH A VERY SHORT TREATMENT–FREE SURVIVAL: RESULTS FROM 2 INDEPENDENT COHORTS

EHA Library, Basile Stamatopoulos, 133199

NON-CODING NOTCH1 MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKAEMIA; THEIR CLINICAL IMPACT IN THE CLL4 CLINICAL TRIAL

EHA Library, Jonathan Strefford, 133200

AN EVALUATION OF THE CLL-IPI SCORE AND COMPREHENSIVE PROGNOSTIC FACTOR ANALYSIS IN PATIENTS WITH R/R CLL IN IDELALISIB PHASE 3 RANDOMIZED STUDIES

EHA Library, Jacob Soumerai, 133202

IMPROVEMENT IN QUALITY OF LIFE AND WELL-BEING IN OLDER PATIENTS WITH TREATMENT-NAÏVE (TN) CLL: RESULTS FROM THE RANDOMIZED PHASE 3 STUDY OF IBRUTINIB (IBR) VERSUS CHLORAMBUCIL (CLB) (RESONATE-2(TM))

EHA Library, Paolo Ghia, 133205

ULTRA DEEP TARGETED NEXT GENERATION SEQUENCING FOR THE DETECTION OF SUBCLONAL TP53 ABERRATIONS IN CLL

EHA Library, Christian Brieghel, 133206

DURABLE TREATMENT-FREE REMISSION AND EFFECTIVE RETREATMENT IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA WHO ACHIEVED A DEEP RESPONSE WITH VENETOCLAX COMBINED WITH RITUXIMAB

EHA Library, Danielle Brander, 133210

ATRIAL FIBRILLATION IN CLL PATIENTS TREATED WITH IBRUTINIB. AN INTERNATIONAL RETROSPECTIVE STUDY

EHA Library, Vincent Levy, 133211

MANAGEMENT OF TRANSAMINASE ELEVATIONS ASSOCIATED WITH IDELALISIB

EHA Library, Paolo Ghia, 133213

EFFICACY AND SAFETY OF FIRST-LINE TREATMENT WITH NILOTINIB IN ELDERLY CHRONIC MYELOID LEUKEMIA PATIENTS

EHA Library, Gabriele Gugliotta, 133218

ASSESSMENT OF THERAPY RESPONSE IN CHRONIC MYELOID LEUKEMIA VIA 1 MONTH BCR-ABL1 TRANSCRIPT DECLINE

EHA Library, Mohamed El Missiry, 133220

IMPACT OF MUTATION-DERIVED ANTIGENS IN IMMUNE RECOGNITION OF HEMATOLOGICAL MALIGNANCIES, SPECIFICALLY MYELOID DYSPLASTIC SYNDROMES (MDS)

EHA Library, Simon Dorfmüller, 133224

VITAMIN C INCREASES VIRAL MIMICRY INDUCED BY 5-AZA-2′-DEOXYCYTIDINE

EHA Library, Andreas Due Ørskov, 133225

GENETIC PREDISPOSITIONS TO SPORADIC MYELOID NEOPLASMS CAUSED BY GERMLINE DDX41 MUTATIONS IN ASIAN AND CAUCASIAN POPULATIONS.

EHA Library, June Takeda, 133226

IMPACT OF SOMATIC MUTATIONS ON OUTCOME IN PATIENTS WITH MDS AFTER STEM-CELL TRANSPLANTATION

EHA Library, Tetsuichi Yoshizato, 133228

17P DELETIONS AND TP53 MUTATIONS IN PATIENTS WITH MDS/AML AND COMPLEX ABERRANT KARYOTYPE

EHA Library, Roxana Schaab, 133229

TP53 AND EZH2 MUTATIONS PREDICT POOR SURVIVAL IN PATIENTS TREATED WITH HYPOMETHYLATING AGENTS IN MDS

EHA Library, M Teresa Cedena, 133230

AZACYTIDINE RESTORES THE ABNORMAL STAT SIGNALING BIOSIGNATURE OF FOXP3+ T REGULATORY CELLS (TREGS) IN RESPONDING MDS PATIENTS.

EHA Library, Ioannis Kotsianidis, 133231

A CULTURE MODEL MIMICKING THE BM-NICHE ALLOWS FOR STUDYING THE DYSREGULATED ERYTHROPOIESIS OF SF3B1 MUTATED MYELODYSPLASTIC SYNDROME WITH RINGED SIDEROBLASTS

EHA Library, Edda Elvarsdóttir, 133232

RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY EVALUATING EPOETIN ALFA VERSUS PLACEBO IN ANEMIC PATIENTS WITH IPSS LOW- INT1 RISK MDS

EHA Library, Pierre Fenaux, 133235

OVERALL SURVIVAL (OS) AND SUBGROUP RESULTS FROM A RANDOMIZED PHASE 2 STUDY OF SGI-110 (GUADECITABINE) IN PREVIOUSLY TREATED MYELODYSPLASTIC SYNDROMES (MDS)

EHA Library, Guillermo Garcia-Manero, 133236

MOLECULAR PROFILING IN A POPULATION BASED COHORT OF NORDIC MYELODYSPLASTIC SYNDROME PATIENTS

EHA Library, Mohsen Karimi, 133238

PHASE 1B STUDY OF GLASDEGIB (PF-04449913) IN COMBINATION WITH AZACITIDINE IN PATIENTS WITH HIGHER RISK MYELODYSPLASTIC SYNDROME, OLIGOBLASTIC ACUTE MYELOID LEUKEMIA, OR CHRONIC MYELOMONOCYTIC LEUKEMIA

EHA Library, Uma Borate, 133242

RESULTS FROM PHASE I/II STUDY OF THE COMBINATION OF ORAL RIGOSERTIB AND AZACITIDINE IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS)

EHA Library, Lewis Silverman, 133243

COMPREHENSIVE CHARACTERIZATION OF THE GENOMIC LANDSCAPE OF MULTIPLE MYELOMA WITH A DELETION OF CHROMOSOME 17P REVEALS A HIGH PREVALENCE OF SOMATIC TP53 MUTATIONS, WHICH CORRELATE WITH A POOR PROGNOSIS

EHA Library, Davine Hofste op Bruinink, 133247

LOSS OF THE INHIBITORY RECEPTOR CD85J/LILRB1 ON MALIGNANT PLASMA CELLS: FROM MGUS TO SYMPTOMATIC MULTIPLE MYELOMA

EHA Library, Ester Lozano, 133250

PROTEIN KINASE CK1A INACTIVATION IN MULTIPLE MYELOMA EMPOWERS LENALIDOMIDE INDUCED CYTOTOXICITY AND CELL CYCLE ARREST

EHA Library, Sabrina Manni, 133251

QUANTIFICATION OF CYCLIN D1, CYCLIN D2, IKAROS, AIOLOS AND CEREBLON PROTEINS BY CAPILARY IMMUNOASSAY IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AND ANALYSIS OF THEIR IMPACT ON PATIENT SURVIVAL

EHA Library, Irena Misiewicz-Krzeminska, 133252

DEVELOPMENT AND IMPLEMENTATION OF A HIGH-THROUGHPUT SEQUENCING BASED, CLINICALLY-FOCUSED, COMPREHENSIVE GENOMIC CHARACTERISATION OF MYELOMA WITHIN A MOLECULAR DIAGNOSTIC SERVICE

EHA Library, Piers Blombery, 133254

IMPACT OF CYTOGENETIC RISK STATUS ON EFFICACY AND SAFETY OF IXAZOMIB-LENALIDOMIDE-DEXAMETHASONE (IRD) VS PLACEBO-RD IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS IN THE GLOBAL TOURMALINE-MM1 STUDY

EHA Library, Hervé Avet-Loiseau, 133256

HIGH CUT-OFF HAEMODIALYSIS (HCO-HD) DOES NOT IMPROVE OUTCOMES IN MYELOMA CAST NEPHROPATHY: RESULTS OF EUROPEAN TRIAL OF FREE LIGHT CHAIN REMOVAL BY EXTENDED HAEMODIALYSIS IN CAST NEPHROPATHY (EULITE)

EHA Library, Mark Cook, 133257

OPROZOMIB, POMALIDOMIDE, AND DEXAMETHASONE (OPOMD) IN PATIENTS (PTS) WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM): INITIAL RESULTS OF A PHASE 1B STUDY (NCT01999335)

EHA Library, Jatin Shah, 133258

PHASE 1B STUDY OF VENETOCLAX COMBINED WITH BORTEZOMIB AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Philippe Moreau, 133259

A PHASE IB STUDY OF THE AKT INHIBITOR AFURESERTIB IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: FINAL RESULTS WITH LONG TERM FOLLOW-UP

EHA Library, Suzanne Trudel, 133260

UPDATED DATA FROM A PHASE II DOSE FINDING TRIAL OF SINGLE AGENT ISATUXIMAB (SAR650984, ANTI-CD38 MAB) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

EHA Library, Meletios Dimopoulos, 133261

CARFILZOMIB, LENALIDOMIDE, AND DEXAMETHASONE VS LENALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA: ANALYSIS OF RESPONSE AND PROGRESSION-FREE SURVIVAL HAZARD RATIO OVER TIME

EHA Library, Meletios Dimopoulos, 133262

A PHASE IB DOSE-ESCALATION TRIAL OF ISATUXIMAB (SAR650984, ANTI-CD38 MAB) PLUS LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): INTERIM RESULTS FROM 2 NEW DOSE COHORTS

EHA Library, Ai-Min HUI, 133265

MOR202 ALONE AND IN COMBINATION WITH POMALIDOMIDE OR LENALIDOMIDE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: DATA FROM CLINICALLY RELEVANT COHORTS FROM A PHASE I/IIA STUDY

EHA Library, Marc S. Raab, 133266

FINAL PHASE 2 STUDY DATA OF MELFLUFEN AND DEXAMETHASONE FOR PATIENTS WITH RELAPSED-REFRACTORY MULTIPLE MYELOMA (RRMM)

EHA Library, Antonio Palumbo, 133268

LOW INCIDENCE OF SKELETAL-RELATED EVENTS AT THE TIME OF FIRST RELAPSE IN PATIENTS WITH MULTIPLE MYELOMA WHO RECEIVED BORTEZOMIB-BASED REGIMENS AS FIRST LINE TREATMENT

EHA Library, Evangelos Terpos, 133272

ACE-1332 (TGFB LIGAND TRAP) INHIBITS ELEVATED TGFΒ1 SIGNALING AND REDUCES FIBROSIS IN A MURINE MODEL OF MYELOFIBROSIS

EHA Library, Rajasekhar NVS Suragani, 133275

DIFFERENTIATION RESPONSE TO GILTERITINIB (ASP2215) IN RELAPSED/REFRACTORY FLT3 MUTATED ACUTE MYELOID LEUKEMIA PATIENTS IS ASSOCIATED WITH CO-MUTATIONS IN NPM1 AND DNMT3A

EHA Library, Jonathan Canaani, 133176

PHASE IB/II STUDY OF NIVOLUMAB IN COMBINATION WITH 5-AZACYTIDINE (AZA) IN PATIENTS (PTS) WITH RELAPSED ACUTE MYELOID LEUKEMIA (AML)

EHA Library, Naval Daver, 133177

CLINICAL RESPONSE IN RELAPSED/REFRACTORY AML PATIENTS CORRELATES WITH LEUKEMIC BLAST MOBILIZATION AND DIFFERENTIATION INDUCED BY BL-8040, A POTENT CXCR4 ANTAGONIST; RESULTS OF A PHASE IIA STUDY

EHA Library, Yaron Pereg, 133178

RESULTS OF A PHASE I STUDY OF GMI-1271, A NOVEL E-SELECTIN ANTAGONIST IN COMBINATION WITH INDUCTION CHEMOTHERAPY IN RELAPSED/REFRACTORY AML: A NOVEL, WELL-TOLERATED REGIMEN WITH A HIGH REMISSION RATE

EHA Library, Helen Thackray, 133179

A PHASE I TRIAL OF A PHARMACODYNAMICALLY-CONCEIVED DECITABINE/THIOGUANINE COMBINATION IN PATIENTS WITH ADVANCED MYELOID MALIGNANCIES

EHA Library, Mark Frattini, 133181

GENOMIC CHARACTERIZATION OF HIGH-COUNT MBL INDIVIDUALS INDICATES THAT EARLYDETECTION OF DRIVER MUTATIONS AND SUBCLONAL EXPANSION ARE PREDICTORS OF ADVERSECLINICAL OUTCOME

EHA Library, Santiago Barrio, 133182

IBRUTINIB INHIBITS CD20 UP-REGULATION ON CLL B CELLS MEDIATED BY THE CXCR4/SDF-1 AXIS

EHA Library, Gabriela Pavlasova, 133188

FUNCTIONAL IMPACT OF BONE MARROW MESENCHYMAL STROMAL CELL-DERIVED EXTRACELLULAR VESICLES ON CHRONIC LYMPHOCYTIC LEUKEMIA B-CELLS: APOPTOSIS, MIGRATION, CHEMORESISTANCE AND GENE EXPRESSION MODIFICATION

EHA Library, Emerence Crompot, 133189

BLOCKING ENDOTHELIN-1 SIGNALING DISRUPTS LEUKEMIC CELL HOMING AND B-CELL RECEPTOR PATHWAY IN CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Rossana Maffei, 133192

GENE EXPRESSION PROFILES OF PERIPHERAL BLOOD T AND NK-CELLS REVEALED DIFFERENT PATTERNS OF IMMUNE DYSFUNCTION IN CLL-LIKE MBL AND EARLY STAGE CLL

EHA Library, Anna Puiggros, 133193

REAL-WORLD EXPERIENCE OF IBRUTINIB IN >2900 CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS: DATA FROM A GLOBAL NAMED PATIENT PROGRAM

EHA Library, Peter Hillmen, 133196

IMPACT OF ADDING RITUXIMAB TO VENETOCLAX ON THE RATE, QUALITY, AND DURATION OF RESPONSE IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKAEMIA: A CROSS-STUDY MULTIVARIABLE ANALYSIS

EHA Library, Andrew W Roberts, 133197

PRELIMINARY RESULTS OF A PHASE II STUDY OF IBRUTINIB IN COMBINATION WITH FCR (IFCR) IN PREVIOUSLY UNTREATED, YOUNGER PATIENTS WITH CLL

EHA Library, Matthew Davids, 133198

UPDATED RESULTS OF A PHASE 3 RANDOMIZED, CONTROLLED STUDY OF IDELALISIB IN COMBINATION WITH OFATUMUMAB FOR PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

EHA Library, Tadeusz Robak, 133201

DISCONTINUATION OF IDELALISIB TREATMENT DUE TO DISEASE PROGRESSION IN PATIENTS WITH RELAPSED AND REFRACTORY CLL: AN EVALUATION OF OUTCOMES

EHA Library, Jennifer R. Brown, 133203

ASSOCIATION BETWEEN KIR/HLA GENOTYPE AND OUTCOME IN THE CLL11 STUDY OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS RECEIVING CHLORAMBUCIL ALONE OR IN COMBINATION WITH OBINUTUZUMAB OR RITUXIMAB

EHA Library, Grzegorz Terszowski, 133204

COMPARABLE OUTCOMES IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH REDUCED­ DOSE IBRUTINIB: RESULTS FROM A MULTI­-CENTER STUDY

EHA Library, Rahul Banerjee, 133207

PATIENTS WITH COMPLEX KARYOTYPE (CK) LACKING TP53 DELETIONS SHOW AN EQUIVALENT DISMAL CLINICAL OUTCOME AS THOSE WITH TP53 DELETIONS AND NON-CK IN CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Anna Puiggros, 133208

LARGE SCALE, REAL-WORLD RESULTS ON IBRUTINIB FOR 428 FRENCH PATIENTS WITH 17P DELETION OR RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA INCLUDED IN A TEMPORARY AUTHORIZATION FOR USE (ATU) PROGRAM

EHA Library, Loïc Ysebaert, 133209

INTEGRATED SAFETY ANALYSIS OF VENETOCLAX MONOTHERAPY IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

EHA Library, Matthew S Davids, 133212

LONG-TERM EFFICACY AND SAFETY OF PONATINIB IN HEAVILY PRETREATED LEUKEMIA PATIENTS: 4-YEAR RESULTS FROM THE PIVOTAL PHASE 2 PACE TRIAL

EHA Library, Jorge Cortes, 133215

SUCCESSFUL TREATMENT FREE REMISSION IN CML AFTER 2 YEAR CONSOLIDATION WITH NILOTINIB OF AN MR4.5 RESPONSE LEVEL ACHIEVED ORIGINALLY WITH IMATINIB TREATMENT: FIRST REPORT FROM STAT2 TRIAL IN JAPAN

EHA Library, Naoto Takahashi, 133216

IMPACT OF SECOND DECLINE RATE OF BCR-ABL1 TRANSCRIPT BETWEEN M3 AND M6 ON CLINICAL OUTCOME FOR CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH IMATINIB: PRACTICAL ASPECT FOR THE TRUE LIFE

EHA Library, G Etienne, 133217

LATE RELAPSES, UP TO 45 MONTHS AFTER IMATINIB DISCONTINUATION: RESULTS FROM THE ISAV STUDY

EHA Library, Silvia Mori, 133219

DEVELOPMENT AND EVALUATION OF A MR1 – MR4.5 SECONDARY LYOPHILIZED CELL REFERENCE PANEL FOR BCR-ABL1 QUANTIFICATION ON THE INTERNATIONAL SCALE

EHA Library, Nick Cross, 133221

TYROSINE KINASE INHIBITORS DISCONTINUATION IN CHRONIC MYELOID LEUKEMIA: A RETROSPECTIVE ANALYSIS OF 208 ITALIAN PATIENTS

EHA Library, Carmen Fava, 133222

MANAGING CHILDREN AND ADOLESCENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH HIGH-DOSE IMATINIB. THE ITALIAN EXPERIENCE.

EHA Library, Fiorina , 133223

IDENTIFICATION OF ALTERED AND CRYPTIC-SPLICING IN SF3B1 MUTANT MYELODYSPLASTIC SYNDROMES AND ISOGENIC MODELS OF SF3B1-K700E MUTATION

EHA Library, Fabio Liberante, 133227

THE INCIDENCE AND CLINICAL IMPLICATIONS OF CHROMOTHRIPSIS IN BONE MARROW CELLS OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS)

EHA Library, Zuzana Zemanova, 133233

MODEST EPIGENETIC EFFECT OF AZACITIDINE IN GENOME-WIDE MAPPING OF DNA METHYLATION, H3K9ME3, H3K18AC AND GENE EXPRESSION IN MDS PROGENITORS.

EHA Library, Magnus Tobiasson, 133234

MUTATIONS OF COHESIN COMPLEX GENES IN MYELODYSPLASTIC SYNDROME: DISTINCT CLINIC-BIOLOGICAL FEATURES AND PROGNOSTIC RELEVANCE

EHA Library, Lo-Ho Chen, 133237

CLINICAL BENEFIT AMONG LENALIDOMIDE (LEN)-TREATED PATIENTS (PTS) WITH RBC TRANSFUSION-DEPENDENT (RBC-TD) LOW-/INT-1-RISK MYELODYSPLASTIC SYNDROMES (MDS) WITHOUT DEL(5Q)

EHA Library, Guillermo Garcia-Manero, 133239

PHASE 1 DOSE-ESCALATION STUDY OF ORAL ASTX727, A COMBINATION OF ORAL DECITABINE WITH A CYTIDINE DEAMINASE INHIBITOR (CDAI) E7727, IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES (MDS)

EHA Library, Michael Robert Savona, 133240

THE USE OF A HIGH DENSITY, 2.6 MILLION MARKER, SNP ARRAY AS THE PRIMARY GENETIC TEST FOR MYELODYSPLASTIC SYNDROME AT DIAGNOSIS: INTERIM FINDINGS OF THE WEST MIDLANDS, UK STUDY

EHA Library, Nicola Trim, 133241

FREQUENT MUTATIONS IN EPIGENETIC REGULATORS IN CYTOPENIA OF UNDETERMINED SIGNIFICANCE:  ASSOCIATION WITH RISK OF PROGRESSION TO MYELODYSPLASTIC SYNDROME

EHA Library, Jakob Werner Hansen, 133244

MOLECULAR AND CLINICAL TYPES OF PLASMA CELL DYSCRASIAS ARE ASSOCIATED WITH DISTINCT EXPRESSION PATTERNS OF LONG NONCODING RNAS

EHA Library, Martina Manzoni, 133245

RPL5 ON 1P22 IS RECURRENTLY DELETED IN MULTIPLE MYELOMA AND ITS EXPRESSION IS LINKED TO BORTEZOMIB RESPONSE

EHA Library, Isabel Hofman, 133246

DEPENDENCE ON GLUTAMINE UPTAKE OF MYELOMA CELLS DELINEATES A NEW ATTRACTIVE THERAPEUTIC STRATEGY

EHA Library, Marina Bolzoni, 133248

LOSS OF PRIMING OR MCL-1 DEPENDENCY CONFERRED ACQUIRED RESISTANCE TO VENETOCLAX IN MULTIPLE MYELOMA

EHA Library, Martine Amiot, 133249

DEFERASIROX INDUCES APOPTOSIS THROUGH INHIBITION OF ONCOGENIC PYK2/BETA-CATENIN SIGNALING IN MULTIPLE MYELOMA CELLS

EHA Library, Yusuke Kamihara, 133253

DYNAMIC EVOLUTION OF COPY NUMBER ABERRATIONS ACCOMPANIES DISEASE RELAPSE IN MULTIPLE MYELOMA

EHA Library, Martin Kaiser, 133255

THE SKY92 PROGNOSTIC MARKER IS VALIDATED IN EIGHT MULTIPLE MYELOMA CLINICAL DATASETS

EHA Library, Martin van Vliet, 133263

A PHASE 1B/2 STUDY OF SELINEXOR IN COMBINATION WITH BACKCONE THERAPIES FOR TREATMENT OF RELAPSED/REFACTORY MULTIPLE MYELOMA

EHA Library, Nizar J Bahlis, 133264

ELOTUZUMAB + LENALIDOMIDE/DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: ELOQUENT-2 POST-HOC ANALYSIS OF PFS AND TUMOR REGROWTH BY TIME FROM DIAGNOSIS AND PRIOR LINES OF THERAPY

EHA Library, Meletios Dimopoulos, 133267

PRECISION AS PART OF THE ANALYTICAL VALIDATION OF THE SKY92 HIGH RISK SIGNATURE AND THE MMPROFILER ASSAY

EHA Library, Martin van Vliet, 133269

RISK STRATIFICATION BY SKY92+ISS OUTPERFORMS IFISH MARKERS T(4;14) AND DEL(17P) IN MULTIPLE MYELOMA

EHA Library, Martin van Vliet, 133270

CONSOLIDATION WITH BORTEZOMIB AND LENALIDOMIDE POST-ASCT WITHOUT DEXAMETHASONE AND BISPHOSPHONATES: FINAL ANALYSIS OF A PROSPECTIVE STUDY IN NEWLY DIAGNOSED MYELOMA PATIENTS

EHA Library, Evangelos Terpos, 133271

PHARMACODYNAMIC RELATIONSHIP BETWEEN NATURAL KILLER CELLS AND DARATUMUMAB EXPOSURE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Tine Casneuf, 133273

CONCURRENT INHIBITION OF PI3K/MTOR AND JAK1/JAK2 PATHWAYS PROMPTS COMPLETE DEPHOSPHORYLATION OF STAT5 PROVIDING SYNERGISTIC ACTIVITY IN MPN MODELS

EHA Library, Manjola Balliu, 133274